Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Precision radiation boost may curb rare Cancer's return

NCT ID NCT01841047

Disease control Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether giving a higher dose (54 Gy) of a very precise type of radiation called helical tomotherapy before surgery could improve outcomes for people with retroperitoneal liposarcoma, a rare cancer in the abdomen. The 48 participants received the radiation and then had surgery. The main goal was to see how many people remained free of local recurrence three years later. The results help understand if this more intense radiation approach is worth further study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
helical tomotherapy radiotherapy (54 Gy)
What this could lead to
If successful, this approach could offer a way to reduce local recurrence of retroperitoneal liposarcoma after surgery.
What could go wrong
This was a small, early-phase study (48 participants) with no control group, so results may not be generalizable. The higher radiation dose also carries increased risk of organ toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

48 people

The number who actually took part.

Started

Jan 2009

Finished

Dec 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Liposarcoma histologically proven, in case of non-contributive biopsy: diagnosis radiologically validated within a multidisciplinary meeting 2. Protocol TOMOREP technically feasible, 3. Patients over 18 years 4. Considered as resectable even if multi-visceral excision is needed 5. Absence of morbidity contra-indicating surgery. The evaluation will be performed by the surgeon or the radiotherapist according to the definitions by the ASA classification. 6. Original form (as well as tumors made after first incomplete excision) and form in first relapse. 7. Life expectancy greater than 6 months 8. Patient signed informed consent, 9. Patient affiliated to a social security. Exclusion Criteria: 1. Metastasis associated 2. Extension intraperitoneal associated, mesenteric extension 3. bilaterally 4. Against disease-indicating the need for surgery (ASA 3 and 4). 5. Contra-indication to radiotherapy (such as prior radiotherapy into the volume to treat). 6. Patient included in another clinical trial 7. Patient unable to undergo medical monitoring test for any geographical, social or psychological reasons, 8. Private patient freedom and major subject of a measure of legal protection or unable to consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liposarcoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

liposarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liposarcoma

Contacts and locations

Locations

  • Centre Claudius Regaud

    Toulouse, Midi-Pyrénées, 31000, France

  • Centre Paul Strauss

    Strasbourg, Alsace, 67000, France

  • Centre René Gauducheau

    Nantes, Pays de la Loire Region, 44000, France

  • Institut Bergonié

    Bordeaux, Aquitaine, 33000, France

  • Institut Curie

    Paris, Île-de-France Region, 75000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.